Eddingpharm acquires most ACT assets including telatinib
This article was originally published in Scrip
Executive Summary
In the latest in a string of licensing deals over the past six months, the Chinese firm Eddingpharm has acquired most of the pipeline assets of the private US venture ACT Biotech, including its lead Phase III-ready molecule for stomach cancer.
You may also be interested in...
EOC Gears To Evolve Into Integrated Oncology Company
Oncology focused startup EOC Pharma expects to develop an “exciting” pipeline in two years via the licensing model. The company is also seeking “constant” financing as it advances three drug candidates into the next stage in 2018, EOC CEO Xiaoming Zou tells Scrip in an interview.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.